亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

已收盘 12-19 16:08:47

44.150

+2.850

+6.90%

最高44.650	最低39.700	成交量482.67万
今开40.850	昨收41.300	日振幅11.99%
总市值139.02亿	流通市值139.02亿	总股本3.15亿
成交额2.09亿	换手率1.53%	流通股本3.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":44.15,"timestamp":1734595727022,"preClose":41.3,"halted":0,"volume":4826686,"delay":0,"floatShares":314876989,"shares":314876989,"eps":-3.5173647,"marketStatus":"已收盘","marketStatusCode":5,"change":2.85,"latestTime":"12-19 16:08:47","open":40.85,"high":44.65,"low":39.7,"amount":208676584,"amplitude":0.119855,"askPrice":44.2,"askSize":4800,"bidPrice":44.15,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-1.3285889950545091,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1572192000000,"adjPreClose":41.3,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":2.114604,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2492115400","title":"港股异动 | 亚盛医药-B(06855)午后涨超7% 耐立克和APG-2575展现突出疗效 机构看好公司未来营收高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2492115400","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492115400?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:39","pubTimestamp":1734586744,"startTime":"0","endTime":"0","summary":"消息面上，亚盛医药的耐立克与APG-2575 均在ASH大会上展现多项临床数据。同时，APG-2575在MM和MDS中均展现良好的初步疗效数据。展望未来，全球上市加速，核心产品有望于2026-2027年进入美国市场，预计在2024年APG-2575将递交NDA申请，并于2025年在中国获批上市，同时耐立克医保覆盖范围将进一步增加。此外，耐立克预计在2026年完成POLARIS-2临床试验并在美国提交NDA 申请，最快可于同年在美国上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","06855","APG"],"gpt_icon":0},{"id":"2492113984","title":"亚盛医药-B盘中异动 快速拉升5.21%报43.450港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492113984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492113984?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:00","pubTimestamp":1734584431,"startTime":"0","endTime":"0","summary":"2024年12月19日下午盘13时00分，亚盛医药-B股票出现波动，股价大幅上涨5.21%。截至发稿，该股报43.450港元/股，成交量137.45万股，换手率0.44%，振幅9.08%。资金方面，该股资金流入2926.11万港元，流出1748.92万港元。亚盛医药-B股票所在的生物技术行业中，整体跌幅为0.82%。其相关个股中，永泰生物-B、思路迪医药股份、亚盛医药-B涨幅较大，振幅较大的相关个股有来凯医药-B、永泰生物-B、晶泰控股-P，振幅分别为18.50%、17.54%、13.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219130032a1fa48f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219130032a1fa48f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","06855","BK1574"],"gpt_icon":0},{"id":"2492975505","title":"【券商聚焦】中信建投维持亚盛医药(06855)“买入”评级 指在重磅BIC潜力产品带动下未来营收有望保持高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2492975505","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492975505?lang=zh_cn&edition=full","pubTime":"2024-12-18 15:30","pubTimestamp":1734507031,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，亚盛医药 的耐立克与APG-2575均在ASH大会上展现多项临床数据。其中，耐立克在二线CP-CML患者中展现良好数据，74%的患者治疗后获CCyR，并且产品在Asciminib耐药后的患者中依旧展现37.5%的CCyR，疗效出色。该行指，公司已在血癌和实体瘤等领域搭建多个产品管线，在重磅BIC潜力产品的带动下未来营收有望持续保持高增长。该行预计亚盛医药2024-2026年将实现9.81、5.68、8.77亿元的收入，同比增长341.93%、-42.10%、54.45%，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2EzOTlkNjExODQ0M2ZhODVjNjcxNDk5OTNhMDU4MjE2MzgxODI2NTQy.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949895","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","09939","159938"],"gpt_icon":0},{"id":"2492505947","title":"以全球创新为抓手迈向国际化纵深，亚盛医药(6855.HK)获“年度卓越大健康企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2492505947","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492505947?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:49","pubTimestamp":1734490161,"startTime":"0","endTime":"0","summary":"在日前第九届“格隆汇·全球投资嘉年华·2025”上揭晓的“金格奖”年度卓越公司评选中，亚盛医药(6855.HK)荣获“年度卓越大健康企业”奖项，受到市场关注。","market":"sg","thumbnail":"https://img7.gelonghui.com/column/10.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/10.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1495322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06855","09939","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2491651495","title":"亚盛医药-B12月16日主力资金流出563万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491651495","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491651495?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:15","pubTimestamp":1734336935,"startTime":"0","endTime":"0","summary":"12月16日, 亚盛医药-B股价涨1.16%，报收39.15元，成交金额1.14亿元，换手率0.93%，振幅4.39%，量比1.57。亚盛医药-B今日主力资金净流出563万元，连续3日净流出，上一交易日主力净流出296万元，今日环比增加90.20%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为70.00%，平均跌幅为2.91%。该股近5个交易日下跌7.03%，主力资金累计净流出1749万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出2049万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161555ab7bc8bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161555ab7bc8bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","09939","06855","BK1161"],"gpt_icon":0},{"id":"2491301073","title":"格隆汇沽空预警榜 | 12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2491301073","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491301073?lang=zh_cn&edition=full","pubTime":"2024-12-14 02:15","pubTimestamp":1734113700,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日大市沽空比例为16.60%，过去两个月大市日均沽空比例为16.07%。其中，安硕纳指一百-U、安硕印度-U、新鸿基地产-R沽空比率排名前三位，分别为100.00%、100.00%、100.00%。恒生中国企业、盈富基金、腾讯控股的沽空金额排名前三位，分别为28.39亿、23.88亿、14.15亿。中国交通建设、香港交易所-R、汇通达网络的偏离值排名前三位，分别为4.46、3.82、3.48。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/14021546383193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0797268264.HKD","HYDD.SI","06683","SG9999000327.SGD","03134","LU0072913022.USD","02817","LU0054237671.USD","HBBD.SI","002594","06855","SG9999001093.SGD","01800","80388","09961","LU0049853897.USD","LU2488822045.USD","03033","01119","81810","BYDDY","TCEHY","HTCD.SI","00148","IE00BZ08YR35.GBP","02443","81211","89618","IE00B543WZ88.USD","80016","02828","80700","09878","01921","02800","00700","01211","09829","81299","07332","82829","89988"],"gpt_icon":1},{"id":"2491392314","title":"亚盛医药-B(06855)下跌5.22%，报39.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491392314","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491392314?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:23","pubTimestamp":1734060229,"startTime":"0","endTime":"0","summary":"12月13日，亚盛医药-B(06855)盘中下跌5.22%，截至11:23，报39.0元/股，成交6134.63万元。亚盛医药集团是一家专注于肿瘤、乙肝及与衰老相关疾病治疗领域的创新药物开发的生物医药企业，拥有自主构建的蛋白-蛋白相互作用靶向药物设计平台，并已建立9个已进入临床开发阶段的1类小分子新药产品管线。公司的核心产品奥雷巴替尼已在中国获批上市，正在全球范围内进行40多项临床试验，且已有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定，2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。截至2024年中报，亚盛医药-B营业总收入8.24亿元、净利润1.63亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/13112346348450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","06855","BK1574","BK1515","09939","BK1161"],"gpt_icon":0},{"id":"2491541392","title":"亚盛医药-B盘中异动 早盘快速下挫5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491541392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491541392?lang=zh_cn&edition=full","pubTime":"2024-12-13 11:23","pubTimestamp":1734060222,"startTime":"0","endTime":"0","summary":"2024年12月13日早盘11时23分，亚盛医药-B股票出现波动，股价快速跳水5.10%。截至发稿，该股报39.050港元/股，成交量153.69万股，换手率0.49%，振幅5.10%。机构评级方面，在所有8家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。亚盛医药-B股票所在的生物技术行业中，整体跌幅为0.65%。亚盛医药-B公司简介：亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121311234295e95577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121311234295e95577&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09939","BK1515","BK1161","06855"],"gpt_icon":0},{"id":"2489230401","title":"亚盛医药-B12月06日遭主力抛售250万元 环比增加278.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489230401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489230401?lang=zh_cn&edition=full","pubTime":"2024-12-06 16:16","pubTimestamp":1733473013,"startTime":"0","endTime":"0","summary":"12月06日, 亚盛医药-B股价涨0.74%，报收40.80元，成交金额6610万元，换手率0.51%，振幅3.46%，量比0.87。亚盛医药-B今日主力资金净流出250万元，连续5日净流出，上一交易日主力净流出66万元，今日环比增加278.79%。该股近5个交易日下跌5.45%，主力资金累计净流出1248万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出1219万元，其中净流出天数为11日。该股主力净额占比0.02%，港股市场排名2531/2648。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161744ab620821&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206161744ab620821&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"2488550931","title":"亚盛医药-B12月04日遭主力抛售634万元 环比增加792.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488550931","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488550931?lang=zh_cn&edition=full","pubTime":"2024-12-04 16:15","pubTimestamp":1733300134,"startTime":"0","endTime":"0","summary":"12月04日, 亚盛医药-B股价涨0.49%，报收41.30元，成交金额6647万元，换手率0.52%，振幅4.50%，量比1.02。亚盛医药-B今日主力资金净流出634万元，连续3日净流出，上一交易日主力净流出71万元，今日环比增加792.96%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为3.05%。该股近5个交易日下跌2.47%，主力资金累计净流出315万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出468万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204161548a26b9c43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204161548a26b9c43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1574","06855","BK1515"],"gpt_icon":0},{"id":"2488612897","title":"亚盛医药-B(6855.HK)：聚力产品创新突破 聚焦国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2488612897","media":"平安证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488612897?lang=zh_cn&edition=full","pubTime":"2024-12-02 00:00","pubTimestamp":1733068800,"startTime":"0","endTime":"0","summary":"APG-2575 治疗R/R CLL/SLL 国内上市申请已获受理，有望成为全球第二款上市BCL-2 抑制剂。全球首款BCL-2 抑制剂维奈克拉分别于2016 年、2018 年在美加速获批治疗CLL/SLL 和AML，2020 年底国内附条件批准治疗AML，开创了细胞凋亡机制在临床治疗中的应用，2022 年产品全球销售额突破20 亿美元，2024 前三季度合计销售额达19 亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202102118a264fb45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202102118a264fb45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"亚盛医药-B(6855.HK)：聚力产品创新突破 聚焦国际化布局","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1515","BK1574","06855"],"gpt_icon":0},{"id":"2487372915","title":"亚盛医药-B(06855)“真创新”价值再获验证，耐立克新适应症纳入新版医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2487372915","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2487372915?lang=zh_cn&edition=full","pubTime":"2024-11-29 10:24","pubTimestamp":1732847045,"startTime":"0","endTime":"0","summary":"11月下旬以来，亚盛医药-B利好消息不断。值得一提的是，随着耐立克在2022年纳入的适应症成功续约，目前该药已上市的所有适应症均已纳入国家医保药品目录。作为亚盛医药首个获批上市的核心品种，耐立克上市一年即获纳入国家医保目录，尔后销量和销售额均迅猛增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","BK1161","BK1574","06855","BK1515"],"gpt_icon":0},{"id":"2486317003","title":"港股公告掘金 |波司登(03998)公布中期业绩 权益股东应占溢利同比上升23%至约11.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486317003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486317003?lang=zh_cn&edition=full","pubTime":"2024-11-28 23:16","pubTimestamp":1732806995,"startTime":"0","endTime":"0","summary":"【重大事项】多点数智(02586)11月28日至12月3日招股 拟全球发售2577.4万股重塑能源(02570)11月28日至12月3日招股 拟全球发售约482.79万股越秀地产(00123)通过公开挂牌方式以78.97亿元竞得上海市浦东杨思地块中银航空租赁(02588)附属购买14架波音737-8飞机康方生物(09926)：开坦尼(卡度尼利)和依达方(依沃西)被纳入国家医保药品目录亚盛医药-B(","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","HSTECH","BK1502","LU1720050803.USD","06855","LU1794554557.SGD","BK1589","LU0348784397.USD","03998","LU0417516571.SGD","LU1808992512.USD","BK1512","BK1191","09926","IE00B5MMRT66.SGD","LU1675838814.USD","BK1500","HSCEI","IE00B543WZ88.USD","00512","BK1574","LU0348783233.USD","YANG","BK1227","LU2488822045.USD","BK1161"],"gpt_icon":1},{"id":"2486436761","title":"【港股通】亚盛医药(06855)原创新药耐立克续约纳入新版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486436761","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486436761?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:43","pubTimestamp":1732783436,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药 公布，公司原创1类新药奥雷巴替尼片新增适应症通过2024年国家医保药品目录调整谈判药品简易续约程序成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。与此同时，耐立克于2022年纳入的适应症成功续约。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjEwODMyZjRkNWI4NjVjNzFhNGY4NWE0ZDExNzMxMDU0NzE5MDIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948613","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","HSTECH","YANG","06978","BK1515","159938","09939","BK1161","BK1574","HSCEI","06855"],"gpt_icon":0},{"id":"2486236245","title":"亚盛医药-B(06855)耐立克®新增适应症纳入新版国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2486236245","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486236245?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:34","pubTimestamp":1732782867,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司原创1类新药奥雷巴替尼片新增适应症通过2024年国家医保药品目录调整谈判药品简易续约程序成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。2021年11月，耐立克于中国获批上市，是国内首个伴T315I突变的CML治疗药物。此次耐立克成功续约及新适应症获纳入新版国家医保目录，将有望大大提升可及性，加速惠及更多、更广泛的中国CML患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","159938","BK1161","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2486708148","title":"亚盛医药-B11月25日主力资金流入163万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708148","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708148?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:16","pubTimestamp":1732522564,"startTime":"0","endTime":"0","summary":"11月25日, 亚盛医药-B股价涨4.03%，报收42.55元，成交金额7465万元，换手率0.56%，振幅5.38%，量比1.23。亚盛医药-B今日主力资金净流入163万元，连续3日净流入，上一交易日主力净流入189万元，今日环比减少13.76%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为69.23%，平均涨幅为4.35%。该股近5个交易日上涨4.41%，主力资金累计净流出104万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出640万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125161639abdd3c3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125161639abdd3c3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2486934744","title":"亚盛医药-B盘中异动 急速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486934744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486934744?lang=zh_cn&edition=full","pubTime":"2024-11-25 09:38","pubTimestamp":1732498735,"startTime":"0","endTime":"0","summary":"2024年11月25日早盘09时38分，亚盛医药-B股票出现异动，股价急速上涨5.01%。截至发稿，该股报42.950港元/股，成交量38.02万股，换手率0.12%，振幅5.38%。亚盛医药-B股票所在的生物技术行业中，整体涨幅为0.19%。其相关个股中，来凯医药-B、亚盛医药-B、再鼎医药涨幅较大，振幅较大的相关个股有晶泰科技、科伦博泰生物-B、来凯医药-B，振幅分别为10.54%、8.87%、8.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125093855971a83cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125093855971a83cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","06855","BK1574","BK1515"],"gpt_icon":0},{"id":"2486531746","title":"亚盛医药-B(06855)：Marina S. Bozilenko及Debra Yu获任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2486531746","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486531746?lang=zh_cn&edition=full","pubTime":"2024-11-25 09:02","pubTimestamp":1732496552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，公司董事会已委任Marina S. Bozilenko及Debra Yu为公司额外独立非执行董事，自2024年11月25日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","06855","BK1515","BK1161","159938","BK1574"],"gpt_icon":0},{"id":"2486254607","title":"亚盛医药任命Marina S. Bozilenko女士、Debra Yu博士为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2486254607","media":"美通社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486254607?lang=zh_cn&edition=full","pubTime":"2024-11-25 08:27","pubTimestamp":1732494420,"startTime":"0","endTime":"0","summary":"马里兰州罗克维尔市和中国苏州2024年11月25日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司任命Marina S. Bozilenko女士、Debra Yu博士为公司独立非执行董事，该任命于2024年11月25日起生效。亚盛医药董事长、CEO杨大俊博士表示：\"我们非常欢迎Marina S. Bozilenko女士和Debra Yu博士成为亚盛医药的独立非执行董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4565074_ZH65074_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["NCI","CDE","BK4202","06855","BK4017","BK1161","BK1574"],"gpt_icon":0},{"id":"2485233356","title":"亚盛医药-B11月22日获主力加仓189万元 环比增加302.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485233356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485233356?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:16","pubTimestamp":1732263392,"startTime":"0","endTime":"0","summary":"11月22日, 亚盛医药-B股价跌3.54%，报收40.90元，成交金额4357万元，换手率0.33%，振幅5.54%，量比0.75。亚盛医药-B今日主力资金净流入189万元，上一交易日主力净流入47万元，今日环比增加302.13%。该股近5个交易日下跌3.76%，主力资金累计净流出529万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1919万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161720abd6d6aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122161720abd6d6aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1515","BK1574","09939"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.0123},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.6653},{"period":"1year","weight":0.5674},{"period":"ytd","weight":0.5128}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351，细胞凋亡靶向药物APG-1252、 APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.061697},{"month":2,"riseRate":0.2,"avgChangeRate":-0.06377},{"month":3,"riseRate":0,"avgChangeRate":-0.152214},{"month":4,"riseRate":0.8,"avgChangeRate":0.111517},{"month":5,"riseRate":0.4,"avgChangeRate":0.061168},{"month":6,"riseRate":0.8,"avgChangeRate":0.262196},{"month":7,"riseRate":0.4,"avgChangeRate":-0.080666},{"month":8,"riseRate":0.8,"avgChangeRate":0.030238},{"month":9,"riseRate":0.2,"avgChangeRate":-0.085141},{"month":10,"riseRate":0.6,"avgChangeRate":0.075164},{"month":11,"riseRate":0.5,"avgChangeRate":0.0779},{"month":12,"riseRate":0.5,"avgChangeRate":0.068963}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}